



SUVEN LIFE SCIENCES LTD

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500 034, Telangana, India.

CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 **Fax:** 91 40 2354 1152 **email:** investorservices@suvan.com **website:** www.suvan.com

EXTRACT OF STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2017

Rs. Lacs

SI No.	Particulars	Quarter ending 31/03/2017 Audited	Year ending 31/03/2017 Audited	Quarter ending 31/03/2016 Audited	Year ended 31/03/2016 Audited	Consolidated Year ending 31/03/2017 Audited	Consolidated Year ending 31/03/2016 Audited
1	Total income from operations	18,014.79	54,447.78	16,937.20	50,028.18	54,447.78	50,028.18
2	Net profit/(loss) for the period (Before tax, exceptional and/or extraordinary items)	4,435.34	15,935.69	4,594.66	12,581.54	12,307.05	9,758.41
3	Net profit/(loss) for the period before tax (After exceptional and/or extraordinary items)	4,435.34	15,935.69	4,594.66	12,581.54	12,307.05	9,758.41
4	Net profit/(loss) for the period After tax (After exceptional and/or extraordinary items)	4,006.97	12,347.37	3,717.80	10,007.99	8,718.73	7,184.86
5	Total comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	4,031.14	12,337.62	3,706.50	9,962.76	8,708.99	7,139.64
6	Equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
7	Reserves (Excluding Revaluation Reserve) as shown in the audited balance sheet.		71,880.10		61,074.42		
8	Earnings Per Share (Of Rs.1.00/- each) (For continuing and discontinued operations) -						
	1. Basic :	3.17	9.69	2.91	7.83	6.84	5.61
	2. Diluted:	3.17	9.69	2.91	7.83	6.84	5.61

Notes

- The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suvan.com .
- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of The Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India . Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34
- The above results were reviewed by the Audit Committee and thereafter approved by the Board of Directors in their meeting held on 13th May 2017 and the same reviewed by the Statutory Auditors .
- The Board has declared and paid an Interim Dividend of Rs.1.00 per equity share (100% of face value of Rs.1.00 each) for the Financial year 2016-17. The Board has recommended that the interim dividend paid will be treated as final dividend for the year 2016-17.
- Reconciliation between financial results previously reported (referred to as "Previous GAAP") and Ind AS for the Quarters/Year presented as under

	Rs. Lacs	
	Qtr ended 31/03/2016	Year ended 31/03/2016
Net profit under previous GAAP (After Tax)	3229.22	9496.98
QIP issue expenses considered for grossing up to share premium account	484.68	484.68
Transitional effect on account of fair valuation of govt loans and reclassification of actuarial loss on employee benefit.	(14.48)	26.32
Deferred tax asset due to fair valuation of Mutual funds & actuarial loss on employee benefit	(5.55)	(23.93)
NET PROFIT UNDER IND AS (AFTER TAX)	3693.87	9984.05
Other comprehensive Income	12.63	(21.29)
TOTAL COMPREHENSIVE INCOME UNDER IND AS	3706.50	9962.76

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI

Chairman & CEO

DIN: 00278028

Place : Hyderabad

Date: 13th May, 2017



SUVEN LIFE SCIENCES LTD

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500 034, Telangana, India.

L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvlen.com website: www.suvlen.com

CIN:

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st Mar ' 2017

PART - I

Sl. No.	PARTICULARS	For the Quarter Ended			Standalone for the year Ended		Consolidated for the year Ended	
		31/03/2017	31/12/2016	31/03/2016	31/03/2017	31/03/2016	31/03/2017	31/3/2016
		Audited	Un-Audited	Audited	Audited	Audited	Audited	Audited
1	Income from operations							
	(a) Net sales/income from operations	17,499.64	11,539.43	16,937.20	53,916.74	50,028.18	53,916.74	50,028.18
	(b) Other operating income	515.15	15.89	-	531.04	-	531.04	-
	Total income from operations (net)	18,014.79	11,555.32	16,937.20	54,447.78	50,028.18	54,447.78	50,028.18
2	Expenses							
	a) Cost of materials consumed	4,235.36	3,852.71	4,664.35	15,480.66	17,845.37	15,480.66	17,845.37
	b) Purchases of stock-in-trade	-	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,234.61	(1,607.90)	1,925.07	(295.94)	(1,205.21)	(295.94)	(1,205.21)
	d) Employee benefits expense	1,453.53	1,262.91	926.49	5,064.46	4,094.43	5,216.57	4,094.43
	e) Depreciation and amortisation expense	718.31	487.20	557.49	2,141.31	1,749.71	2,141.31	1,749.71
	f) Other expenses - Manufacturing Exps	2,531.43	1,975.74	2,172.23	8,157.37	7,522.01	8,157.37	7,522.01
	- R & D Exps	1,923.75	1,635.97	1,600.56	6,494.09	6,217.41	9,914.54	9,035.16
	- Others	819.49	749.64	752.01	3,012.81	2,565.07	3,067.13	2,570.03
	Total expenses	13,916.48	8,356.27	12,598.20	40,054.76	38,788.79	43,681.64	41,611.50
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	4,098.31	3,199.05	4,339.00	14,393.02	11,239.39	10,766.14	8,416.68
4	Other Income	493.85	490.15	423.18	2,109.25	1,929.36	2,109.25	1,929.36
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	4,592.16	3,689.20	4,762.18	16,502.27	13,168.75	12,875.39	10,346.04
6	Finance costs	156.82	126.47	167.52	566.58	587.21	568.34	587.63
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	4,435.34	3,562.73	4,594.66	15,935.69	12,581.54	12,307.05	9,758.41
8	Exceptional Items	-	-	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	4,435.34	3,562.73	4,594.66	15,935.69	12,581.54	12,307.05	9,758.41
10	Tax Expenses	428.37	1,135.66	876.86	3,588.32	2,573.55	3,588.32	2,573.55
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	4,006.97	2,427.07	3,717.80	12,347.37	10,007.99	8,718.73	7,184.86
12	Extraordinary Items (net of tax expense ` ____ Lakhs)	-	-	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	4,006.97	2,427.07	3,717.80	12,347.37	10,007.99	8,718.73	7,184.86
14	Share of profit / (loss) of associates*	-	-	-	-	-	-	-
15	Minority interest *	-	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *	4,006.97	2,427.07	3,717.80	12,347.37	10,007.99	8,718.73	7,184.86
16.a	Other Comprehensive Income	24.17	(11.31)	(11.30)	(9.75)	(45.23)	(9.74)	(45.22)
16.b	Total Comprehensive Income	4,031.14	2,415.76	3,706.50	12,337.62	9,962.76	8,708.99	7,139.64
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,272.82 Re.1.00						
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year					61,074.42		58,255.65
19.i	Earning Per Share (EPS) (before extraordinary items) (of ` Rs.1/- each) (not annualised):							
	a) Basic	3.17	1.90	2.91	9.69	7.83	6.84	5.61
	b) Diluted	3.17	1.90	2.91	9.69	7.83	6.84	5.61
19.ii	Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):							
	a) Basic	3.17	1.90	2.91	9.69	7.83	6.84	5.61
	b) Diluted	3.17	1.90	2.91	9.69	7.83	6.84	5.61

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES								Rs.in Lacs
PARTICULARS	For the Quarter Ended			Standalone for the year Ended		Consolidated for the year Ended		
	31/03/2017	31/12/2016	31/03/2016	31/03/2017	31/03/2016	31/03/2017	31/3/2016	
	Audited	Un-Audited	Audited	Audited	Audited	Audited	Audited	
1 SEGMENT REVENUE :-								
a) Manufacturing (CRAMS)	17,500.16	10,682.46	16,344.52	51,670.07	46,710.87	51,670.07	46,710.87	
b) Services (DDDSS)	514.63	856.99	516.64	2,777.71	3,241.37	2,777.71	3,241.37	
c) Research & Development	-	-	-	-	-	-	-	
Net Sales from Operations	18,014.79	11,539.45	16,861.16	54,447.78	49,952.24	54,447.78	49,952.24	
2 SEGMENT RESULTS :-								
Profit/(Loss) before tax and interest:								
a) Manufacturing (CRAMS)	6,342.38	4,999.12	6,213.67	21,634.85	17,391.75	21,634.85	21,635.15	
b) Services (DDDSS)	275.68	439.15	307.44	1,476.81	1,982.52	1,474.14	1,474.16	
c) Research & Development	(1,923.75)	(1,635.97)	(1,678.23)	(6,494.09)	(6,295.08)	(10,066.65)	(10,066.65)	
TOTAL	4,694.31	3,802.30	4,842.88	16,617.57	13,079.19	13,042.34	13,042.66	
Less: i) Interest	75.01	93.12	109.93	376.38	406.52	376.38	376.38	
ii) Other Un-allocable exps net off un-allocable Income	183.96	146.45	138.28	305.50	91.13	358.91	358.91	
Total Profit Before Tax	4,435.34	3,562.73	4,594.67	15,935.69	12,581.54	12,307.05	12,307.37	
3 SEGMENT ASSETS :								
a) Manufacturing (CRAMS)	43,886.92	51,397.78	43,026.99	43,886.92	43,026.99	43,659.63	43,659.63	
b) Services (DDDSS)	2,828.60	2,693.72	3,879.73	2,828.60	3,879.73	2,818.98	2,818.98	
c) Research & Development	2,609.60	2,489.66	2,626.80	2,609.60	2,626.80	2,860.30	2,860.30	
d) Un allocated	38,291.82	29,713.48	27,816.55	38,291.82	27,816.55	32,232.01	32,222.63	
TOTAL	87,616.94	86,294.64	77,350.07	87,616.94	77,350.07	81,570.92	81,561.54	
SEGMENT LIABILITIES :								
a) Manufacturing (CRAMS)	8,547.86	8,727.74	7,860.96	8,547.86	7,860.96	8,119.53	8,119.29	
b) Services (DDDSS)	370.23	491.00	336.65	370.23	336.65	352.40	352.39	
c) Research & Development	1,848.18	2,113.04	1,683.46	1,848.18	1,683.46	2,721.35	2,721.30	
d) Un allocated	687.22	803.03	548.93	687.22	548.93	667.23	667.21	
TOTAL	11,453.49	12,134.81	10,430.00	11,453.49	10,430.00	11,860.51	11,860.19	

Notes: 1) The above results were reviewed by Audit committee and approved by the Board of Directors' meeting held on 13th May'17 and the same has been Reviewed by the Statutory Auditors.

2) Corresponding Previous period figures have been regrouped / reclassified where ever necessary.

3) The Board has declared and paid an Interim Dividend of Rs.1.00 per equity share (100% of face value of Rs.1.00 each) for the Financial year 2016-17. The Board has recommended that the interim dividend paid will be treated as final dividend for the year 2016-17.

4) The Figures for the Qtr ended 31/3/2017 & 31/3/2016 are the balancing figures between the audited figures in respect of the full financial figures and published year to date figures upto 3rd Qtr of the relevant financial year .

5) Reconciliation between financial results previously reported (referred to as "Previous GAAP") and Ind AS for the Quarters/Year presented as under

	Qtr ended	For the Year Ended
	31/03/2016	31/03/2016
Net profit under previous GAAP (After Tax)	3229.22	9496.98
QIP issue expenses considered for grossing up to share premium account	484.68	484.68
Transitional effect on account of fair valuation of govt loans and reclassification of actuarial loss on employee benefit.	(14.48)	26.32
Deferred tax asset due to fair valuation of Mutual funds & actuarial loss on employee benefits	(5.55)	(23.93)
Net profit under Ind AS (After Tax)	3693.87	9984.05
Other Comprehensive Income	12.63	(21.29)
Total Comprehensive Income Under Ind AS	3706.50	9962.76

For SUVEN LIFE SCIENCES LTD

Place : Hyderabad
Date : 13th May ' 2017

VENKAT JASTI
Chairman & CEO
DIN: 00278028

--- 146 ---